Covalon [COV.v/CVALF]: If an ounce of prevention is worth a pound of cure, then this company's stock should be worth more.
Covalon developed and patented a dual antimocrobial silicone adhesive bandage (chlorhexidine and silver) that was beginning to see some serious sales traction before they licensed it to Molnlycke Healthcare in November 2013 (the largest supplier of clear silicon adhesive bandages worldwide). Sales seam to have stalled in their Fiscal Q1 of 2014 (ending December 2013), but Molnlycke has already launched their product in February 2014 and the next few quarters should be telling of the market potential for these products.
Molnycke's website:
mepitelfilmam.com
Trailing Financial Performance
| Fiscal Quarter | Wound Care Sales | Total Revenue | Earnings | | Q3/2014 | | | | | Q2/2014 | | | | | Q1/2014 | $733,590 | $4,522,201 | $3,120,419 | | Q4/2013 | $1,352,855 | $1,543,019 | $125,319 | | Q3/2013 | $1,411,220 | $1,477,632 | $234,826 | | Q2/2013 | $478,371 | $535,224 | ($558,831) | | Q1/2013 | $520,523 | $578,268 | ($794,481) | | Q4/2012 | $502,715 | $951,134 | ($1,854,874) | | Q3/2012 | $632,749 | $1,085,791 | ($732,308) | | Q2/2012 | $524,247 | $1,100,222 | ($604,146)
|
I completed a more complete overview of the company on the I-Hub message board:
siliconinvestor.com |
